At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 25 enrolled
Drug / intervention
Rituximab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study of Rituximab in Addition to Glucocorticoid in Pretreated Elderly or Unfit Patients With Chronic B Lymphocytic Leukemia
In Brief
A Phase 2 clinical trial evaluating Rituximab and Glucocorticoid for B-Cell Chronic Lymphocytic Leukemia. Completed, enrolled 25 participants across 1 site.
Detailed Summary
The study will test the efficacy rituximab in addition to glucocorticoids for the treatment of B-CLL in elderly or unfit patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsB-Cell Chronic Lymphocytic Leukemia
CountriesLithuania
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2011
First PostedApr 2012
Primary CompletionJan 2016
Study CompletionJun 2019
TodayJul 2026
First PostedApr 12, 2012
Enrollment StartOct 1, 2011
Primary CompletionJan 1, 2016
Study CompletionJun 1, 2019
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 14.2 years ago
Interventions
Rituximabdrug
Rituximab (Rtx) antibody infusions will be administered on Day 1, 2, 3 (cycle 1) and Day 1 (cycles 2 to 4).
Glucocorticoiddrug
Glucocorticoid (either Dexamethasone or Methyl-prednisolone) infusions will be administered on Days 1 to 3 (cycles 1-4(6)) and should precede the Rituximab infusion.